A PYMNTS Company

Japan: Takeda gets Japanese approval for US$62b Shire purchase

By  |  October 18, 2018

Takeda Pharmaceutical announced on Thursday, October 18, that Japan’s Fair Trade Commission had approved its US$62 billion acquisition of Shire, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker. The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the United States, Brazil, and China.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,”Takeda CEO Christophe Weber said in a statement. Takeda is also waiting for a nod from EU antitrust regulators. They are expected to make a decision by November 6, but can open a four-month long investigation if they have serious concerns.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full Content: Endpoints News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.